{
    "eid": "2-s2.0-85160970129",
    "title": "Prognostic Role of 68Ga-PSMA11 PET\u2013Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy",
    "cover-date": "2023-06-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Radiology, Nuclear Medicine and Imaging",
            "@code": "2741",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "68Ga-PSMA11 PET/CT",
        "metastatic prostate cancer",
        "survival",
        "taxane-based chemotherapy",
        "treatment monitoring"
    ],
    "authors": [
        "Lukas Lunger",
        "Maythinee Chantadisai",
        "Amir Karimzadeh",
        "Isabel Rauscher",
        "Calogero D\u2019Alessandria",
        "Benedikt Feuerecker",
        "Thomas Langbein",
        "Robert Tauber",
        "Stefan Schiele",
        "Wolfgang Weber",
        "Matthias Eiber"
    ],
    "citedby-count": 1,
    "ref-count": 21,
    "ref-list": [
        "recent global patterns in prostate cancer incidence and mortality rates",
        "Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry",
        "Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models",
        "Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3",
        "Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study",
        "Monitoring chemotherapy and radiotherapy of solid tumors",
        "Positron-emission tomography and assessment of cancer therapy",
        "Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET/CT imaging: the PSMA PET progression criteria",
        "Preliminary results on response assessment using (68)Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy",
        "Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?",
        "(68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy",
        "PSMA and choline PET for the assessment of response to therapy and survival outcomes in prostate cancer patients: a systematic review from the literature",
        "RECIST 1.1: update and clarification\u2014from the RECIST committee",
        "From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors",
        "World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects",
        "Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT",
        "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)",
        "Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria",
        "Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program"
    ],
    "affiliation": [
        {
            "affiliation-city": "Munich",
            "@id": "60103459",
            "affilname": "Klinikum Rechts der Isar",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60103459",
            "affiliation-country": "Germany"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}